Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Costing ‘the’ MTD … in 2-D

View ORCID ProfileDavid C. Norris
doi: https://doi.org/10.1101/370817
David C. Norris
Precision Methodologies, LLC, Seattle WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David C. Norris
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

ABSTRACT

Background I have previously evaluated the efficiency of one-size-fits-all dosing for single agents in oncology (Norris 2017b). By means of a generic argument based on an Emax-type dose-response model, I showed that one-size-fits-all dosing may roughly halve a drug’s value to society. Since much of the past decade’s ‘innovation’ in oncology dose-finding methodology has involved the development of special methods for combination therapies, a generalization of my earlier investigations to combination dosing seems called-for.

Methods Fundamental to my earlier work was the premise that optimal dose is a characteristic of each individual patient, distributed across the population like any other physiologic characteristic such as height. I generalize that principle here to the 2-dimensional setting of combination dosing with drugs A and B, using a copula to build a bivariate joint distribution of (MTDi,A, MTDi,B) from single-agent marginal densities of MTDi,A and MTDi,B, and interpolating ‘toxicity isocontours’ in the (a, b)-plane between the respective monotherapy intercepts. Within this framework, three distinct notional toxicities are elaborated: one specific to drug A, a second specific to drug B, and a third ‘nonspecific’ toxicity clinically attributable to either drug. The dose-response model of (Norris 2017b) is also generalized to this 2-D scenario, with the addition of an interaction term to provide for a complementary effect from combination dosing. A population of 1,000 patients is simulated, and used as a basis to evaluate population-level efficacy of two pragmatic dose-finding designs: a dose-titration method that maximizes dose-intensity subject to tolerability, and the well-known POCRM method for 1-size-fits-all combination-dose finding. Hypothetical ‘oracular’ methods are also evaluated, to define theoretical upper limits of performance for individualized and 1-size-fits-all dosing respectively.

Results In our simulation, pragmatic titration attains 89% efficiency relative to theoretically optimal individualized dosing, whereas POCRM attains only 55% efficiency. The passage from oracular individualized dosing to oracular 1-size-fits-all dosing incurs an efficiency loss of 33%, while the parallel passage (within the ‘pragmatic’ realm) from titration to POCRM incurs a loss of 38%.

Conclusions In light of the 33% figure above, the greater part of POCRM’s 38% efficiency loss relative to titration appears attributable to POCRM’s 1-size-fits-all nature, rather than to any pragmatic difficulties it confronts. Thus, appeals to pragmatic considerations would seem neither to justify the decision to use 1-size-fits-all dose-finding designs, nor to excuse their inefficiencies

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted July 17, 2018.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Costing ‘the’ MTD … in 2-D
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Costing ‘the’ MTD … in 2-D
David C. Norris
bioRxiv 370817; doi: https://doi.org/10.1101/370817
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Costing ‘the’ MTD … in 2-D
David C. Norris
bioRxiv 370817; doi: https://doi.org/10.1101/370817

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Toxicology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4085)
  • Biochemistry (8755)
  • Bioengineering (6477)
  • Bioinformatics (23331)
  • Biophysics (11740)
  • Cancer Biology (9144)
  • Cell Biology (13237)
  • Clinical Trials (138)
  • Developmental Biology (7410)
  • Ecology (11364)
  • Epidemiology (2066)
  • Evolutionary Biology (15084)
  • Genetics (10397)
  • Genomics (14006)
  • Immunology (9115)
  • Microbiology (22036)
  • Molecular Biology (8777)
  • Neuroscience (47345)
  • Paleontology (350)
  • Pathology (1420)
  • Pharmacology and Toxicology (2480)
  • Physiology (3703)
  • Plant Biology (8045)
  • Scientific Communication and Education (1431)
  • Synthetic Biology (2207)
  • Systems Biology (6014)
  • Zoology (1249)